The short answer
Pharmacologic niacin can weaken insulin aspart’s glucose-lowering effect and worsen glucose control. This is different from claiming that ordinary food-level vitamin B3 causes the same risk.
What this answer covers
Oral niacin, especially high-dose nicotinic acid; nicotinamide and Fiasp’s niacinamide excipient are different exposures.
- Supplement or preparation
- Niacin
- Medication ingredient
- insulin aspart, human
The aspart labels name niacin
NovoLog and Fiasp list niacin among agents that may reduce their blood-glucose-lowering effect. They call for closer glucose monitoring and clinician-directed treatment review when the combination is used.
Clinical evidence concerns a high-dose combination
A large vascular-risk trial of extended-release niacin plus laropiprant found more serious disturbances in diabetes control. It was not an aspart-specific comparison, and laropiprant prevents attributing every outcome to niacin alone.
Fiasp’s ingredient is not the same situation
Fiasp contains niacinamide as an excipient. That formulation feature should not be confused with taking oral high-dose nicotinic acid. Ordinary dietary vitamin B3 also differs from a cholesterol-treatment dose.
Plan starting and stopping
Discuss pharmacologic niacin changes with the diabetes team and review glucose readings. No short spacing interval is established to prevent its systemic effect. Do not raise or lower insulin independently.
Evidence and practical considerations
Side effects & toxicity
Exact aspart labels name niacin as potentially weakening glucose lowering; narrowed to pharmacologic exposure and monitoring, without an exact adverse-event rate.
- Exact scope
- Oral niacin, especially high-dose nicotinic acid; nicotinamide and Fiasp’s niacinamide excipient are different exposures. with Insulin aspart human RxCUI51428 IN; NovoLog/Fiasp formulation and subcutaneous/pump/supervised intravenous routes distinguished.
- Medication form and route
- injected insulin aspart; oral supplement
What remains uncertain
- No source-specific uncertainty removed; no invented event rate or universal insulin adjustment.
Factors that may matter: Exact insulin product; Meal pattern; Dose; Other diabetes treatment; Kidney and liver function; Supplement preparation.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People with diabetes receiving exact insulin-aspart product.
Hypoglycemia can be severe. Meal pattern, activity and added glucose-active agents affect risk. Niacin can decrease glucose-lowering effect. Mild hypoglycemia may be treated with oral glucose; severe episodes need emergency treatment.
How this applies: Exact insulin aspart formulation and route distinguished from other insulins, oral medicines and premixed products; supplement preparation and endpoint limits retained.
Not premixed insulin or all insulin analogs. Product-specific timing and device instructions apply. Fiasp niacinamide excipient is not oral pharmacologic nicotinic acid. Label rates do not measure supplement interactions.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People with diabetes receiving exact insulin-aspart product.
Hypoglycemia can be severe. Meal pattern, activity and added glucose-active agents affect risk. Niacin can decrease glucose-lowering effect. Mild hypoglycemia may be treated with oral glucose; severe episodes need emergency treatment.
How this applies: Exact insulin aspart formulation and route distinguished from other insulins, oral medicines and premixed products; supplement preparation and endpoint limits retained.
Not premixed insulin or all insulin analogs. Product-specific timing and device instructions apply. Fiasp niacinamide excipient is not oral pharmacologic nicotinic acid. Label rates do not measure supplement interactions.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 25,673high-vascular-risk adults.
High-dose niacin-laropiprant increased serious disturbances in diabetes control compared with placebo.
How this applies: Indirect for exact insulin aspart; source medication and supplement formulation are preserved.
Combination product, not ordinary nutritional niacin or a glipizide-specific estimate; no supplement need or protective spacing demonstrated. This does not establish an exact insulin-aspart interaction.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact insulin-aspart article with product, route, botanical and clinical endpoint boundaries. | |
| Research summary published |
Article revision: 303c6fd6540820f1
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.